Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Aligns Antibiotics Guideline To Help Facilitate Global Trials

Executive Summary

The EU regulator says it supports a globally aligned approach to the development of new antimicrobial medicines.

You may also be interested in...



EU Targets Antimicrobials For 'Human Use Only' In Bid To Tackle Resistance

In the latest effort to address the growing problem of antimicrobial resistance, the EU authorities are consulting on a list of products that must not be used in animals, in order to help preserve their efficacy in humans.

Pioneering UK Payment Model For Incentivizing Antibiotic Development Meets Major Milestone

Shionogi and Pfizer are now in commercial discussions after their antibiotics were recommended for use via the UK’s new subscription-style payment model, which will ensure a fixed annual fee is paid to companies regardless of how many prescriptions are issued. The UK is urging other countries to offer similar incentives to help beat global antimicrobial resistance.

European Industry Proposes Incentive To Develop New Antimicrobials

With proposals for an overhaul of the EU medicines legislation due at the end of this year, EFPIA has published its formal response to the European Commission’s consultation with suggestions for facilitating new antibiotic development, testing new regulatory approaches to novel medicines, and tackling medicine shortages.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS146221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel